Compare KGS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | BLTE |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | 2023 | 2021 |
| Metric | KGS | BLTE |
|---|---|---|
| Price | $64.92 | $150.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $57.17 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.7M | 192.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $7.96 | $492.11 |
| P/E Ratio | $330.00 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $30.06 | $59.12 |
| 52 Week High | $77.68 | $200.00 |
| Indicator | KGS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 52.02 |
| Support Level | $55.10 | $146.60 |
| Resistance Level | $77.13 | $151.41 |
| Average True Range (ATR) | 2.99 | 7.16 |
| MACD | -0.58 | -0.10 |
| Stochastic Oscillator | 11.50 | 52.94 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.